Severity of COVID-19 Reinfection Linked to Severity of Initial Infection
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, July 18, 2024 -- The severity of COVID-19 reinfection seems to be associated with the severity of initial infection, according to a study published online July 11 in Communications Medicine.
Emily Hadley, from RTI International in Durham, North Carolina, and colleagues characterized reinfection, examined the development of long COVID, and compared the severity of reinfection to that of original infection using an electronic health record study cohort of more than 3 million patients.
The researchers validated previous findings of reinfection incidence (6.9 percent), most reinfections occurring during the omicron epoch, and evidence of multiple reinfections. For infections in the same epoch, the proportion of long COVID diagnoses was higher following initial infection than reinfection. Lower albumin levels were reported leading up to reinfection, and a significant association was seen for severity between initial infection and reinfection, with a medium effect size. Compared with those who had mild initial infection and reinfection, individuals who experienced severe initial and first reinfection were older in age and had a higher mortality risk.
"This work validates existing characterization of reinfection as most common in the omicron epoch and contributes a novel characterization to the best of our knowledge of lower albumin levels after initial COVID-19 infection and leading up to reinfection," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-19 07:15
Read more
- More Than Half of Heat Deaths Can Be Blamed on Global Warming: Study
- Long-Term Upadacitinib Use Feasible for Adolescents With Atopic Dermatitis
- Science Reveals Why Cancer Immunotherapies Can Sometimes Harm the Heart
- Once Again, Tuberculosis Becomes World's Top Infectious Disease Killer
- No Long-Term Cognitive Effects Seen for Menopausal Hormone Therapy
- President-Elect Trump to Pick Mehmet Oz to Head CMS
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions